The VITAL study: case control studies are hypothesis-generating

Affiliations

¹ LAC+USC Medical Center and the Department of Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA. Electronic address: bspellberg@dhs.lacounty.gov.
² David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.

Comment

Brad Spellberg et al. Lancet Infect Dis. 2016 Aug.

. 2016 Aug;16(8):886.

doi: 10.1016/S1473-3099(16)30154-2.

¹ LAC+USC Medical Center and the Department of Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA. Electronic address: bspellberg@dhs.lacounty.gov.
² David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.

No abstract available

Comment in

The VITAL study: case control studies are hypothesis-generating - Authors' reply.
Cornely OA, Maher RM, Marty FM, Lee M, Vehreschild JJ, Vehreschild MJ. Cornely OA, et al. Lancet Infect Dis. 2016 Aug;16(8):886-7. doi: 10.1016/S1473-3099(16)30192-X. Lancet Infect Dis. 2016. PMID: 27477971 No abstract available.

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Marty FM, et al. Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9. Lancet Infect Dis. 2016. PMID: 26969258 Clinical Trial.